

## Press Release

Zug, 22 June 2012

### **Shareholders' Meeting approved all proposals by the Board of Directors and Management presents confident outlook**

Shareholders approved at today's ordinary Shareholder's Meeting all of the proposals submitted by the Board of Directors. In its presentation the management explained the possible value creation potential of the portfolio based on several promising projects and products of selected companies. In addition, the Chairman announced, that besides the execution of the share buy-back programme, it is the Board's intention, to ask for approval of a tax free cash distribution to the Shareholders at the next ordinary Shareholders' Meeting. This under the condition, that the company has sufficient freely disposable liquidity.

The incumbent board members Robert Ingram, Dr Rudolf Lanz and Hans Peter Hasler (Chairman) were re-elected for a period of three years. Mr. Mario Germano Giuliani, citizen of Lugano, was elected as a member of the Board of Directors for a period of 3 years.

The Shareholder's Meeting approved the reduction of the share capital to CHF 552 million by means of the cancellation of 600'000 registered shares with a par value of CHF 60 each. Following the corresponding entry in the Commercial Register, there will therefore be 9,200,000 registered shares issued with a par value of CHF 60 each.

The Shareholders' Meeting authorized the launch of a new share buy-back programme that extends to a maximum of 10% outstanding shares ("2012 buy-back programme"), by means of cancellation of the shares and capital reduction. Before the 2012 share buy-back programme is launched, the share buy-back programme adopted in September 2009 will be terminated.

Further, the shareholders approved the change of name to "HBM Healthcare Investments AG". The name change reflects the Investment Guidelines, adopted by the Board of Directors in June 2010, aiming at the broadening of the investment segment by focusing more on companies with predictable business growth and less on traditional venture capital financing.

The presentation shown at the Shareholders' Meeting is available via the HBM BioVentures website [www.hbmbioventures.com](http://www.hbmbioventures.com). For further information, please contact Dr. Andreas Wicki, CEO, HBM BioVentures Ltd, tel.: +41 41 768 11 08, [andreas.wicki@hbmbioventures.com](mailto:andreas.wicki@hbmbioventures.com).

# NOT FOR DISTRIBUTION IN USA, CANADA, JAPAN OR AUSTRALIA

**HBM BioVentures**

**HBM Healthcare  
Investments**

## Profile of HBM BioVentures AG

HBM BioVentures invests in the healthcare sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM BioVentures an interesting alternative to investing in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

## Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

**HBM BioVentures Ltd**

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | [info@hbmbioventures.com](mailto:info@hbmbioventures.com)  
[www.hbmbioventures.com](http://www.hbmbioventures.com)